Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors

por Suebsuwong, Chalada, Pinkas, Daniel M., Ray, Soumya S., Bufton, Joshua C., Dai, Bing, Bullock, Alex N., Degterev, Alexei, Cuny, Gregory D.
Publicado 2018

Characterization and structure of the human lysine-2-oxoglutarate reductase domain, a novel therapeutic target for treatment of glutaric aciduria type 1

por Leandro, João, Khamrui, Susmita, Suebsuwong, Chalada, Chen, Peng-Jen, Secor, Cody, Dodatko, Tetyana, Yu, Chunli, Sanchez, Roberto, DeVita, Robert J., Houten, Sander M., Lazarus, Michael B.
Publicado 2022

Synthesis, in Vitro Evaluation and Cocrystal Structure of 4-Oxo-[1]benzopyrano[4,3-c]pyrazole Cryptosporidium parvum Inosine 5′-Monophosphate Dehydrogenase (CpIMPDH) Inhibitors

por Sun, Zhuming, Khan, Jihan, Makowska-Grzyska, Magdalena, Zhang, Minjia, Cho, Joon Hyung, Suebsuwong, Chalada, Vo, Pascal, Gollapalli, Deviprasad R., Kim, Youngchang, Joachimiak, Andrzej, Hedstrom, Lizbeth, Cuny, Gregory D.
Publicado 2014

Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors

por Canning, Peter, Ruan, Qui, Schwerd, Tobias, Hrdinka, Matous, Maki, Jenny L., Saleh, Danish, Suebsuwong, Chalada, Ray, Soumya, Brennan, Paul E., Cuny, Gregory D., Uhlig, Holm H., Gyrd-Hansen, Mads, Degterev, Alexei, Bullock, Alex N.
Publicado 2015

Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling

por Hrdinka, Matous, Schlicher, Lisa, Dai, Bing, Pinkas, Daniel M, Bufton, Joshua C, Picaud, Sarah, Ward, Jennifer A, Rogers, Catherine, Suebsuwong, Chalada, Nikhar, Sameer, Cuny, Gregory D, Huber, Kilian VM, Filippakopoulos, Panagis, Bullock, Alex N, Degterev, Alexei, Gyrd‐Hansen, Mads
Publicado 2018